These results provide the first head-to-head comparison of alectinib and crizotinib and have the potential to change the standard of care for the first-line treatment of ALK-positive non-small-cell lung cancer. The dose of alectinib (300 mg twice daily) used in this study is lower than the approved dose in countries other than Japan; however, this limitation is being addressed in the ongoing ALEX study. READ ARTICLE
Lancet DOI: 10.1016/S0140-6736(17)30565-2
Authors: Toyoaki Hida MD, Hiroshi Nokihara MD, Masashi Kondo MD, Young Hak Kim MD, Koichi Azuma MD, Takashi Seto MD, Yuichi Takiguchi MD, Makoto Nishio MD, Hiroshige Yoshioka MD, Fumio Imamura MD, Katsuyuki Hotta MD, Satoshi Watanabe MD, Koichi Goto MD, Miyako Satouchi MD, Toshiyuki Kozuki MD, Takehito Shukuya MD, Kazuhiko Nakagawa MD, Tetsuya Mitsudomi MD, Nobuyuki Yamamoto MD,Takashi Asakawa PhD, Ryoichi Asabe MS, Tomohiro Tanaka MS, Tomohide Tamura MD